Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GeneNews, a molecular diagnostics company, has appointed David Sable to its board of directors. Dr Sable directs all life sciences investing for the Special Situations Funds based in New York.
Subscribe to our email newsletter
Dr Sable has served as resident and chief resident in obstetrics and gynecology at New York Hospital-Cornell Medical Center and as fellow in reproductive endocrinology at the Brigham and Women’s Hospital in Boston.
Rory Riggs, chairman of board of directors of GeneNews, said: “Special Situations is a leader amongst US life sciences funds and one of our core investors. Dr Sable brings a deep knowledge of the challenges and opportunities facing companies in the biotech and diagnostic space and has broad relationships across the industry.
“This expertise, in addition to Dr Sable’s experience in clinical medicine will provide GeneNews with valuable insights as we continue with the roll out of our ColonSentry test and look forward to the development and commercialization of additional tests based on our Sentinel Principle platform technology.”